Mesoblast (ASX:MSB) is set to launch its Ryoncil mesenchymal stromal cell therapy in the US during the first quarter for pediatric patients two months and older with steroid-refractory acute graft-versus-host disease, according to a Friday Australian bourse filing.
The therapy was approved by the US Food and Drug Administration in December 2024. The firm is now awaiting national drug codes from the regulator, which will allow for the publication of product pricing in the US price compendia.
The firm's commercial inventory has been manufactured and a distribution network has been established using specialty pharmaceutical services and distribution firm Cencora.
Its commercial launch strategy will initially target centers with experience using the therapy at high volume, followed by a broader staged rollout.
The firm has been working on finalizing product availability, including logistics, regulatory documentation, and contractual arrangements ahead of the launch, its chief executive Silviu Itescu said.
It is also collaborating with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) in the US to conduct a trial in adults with the disease.
The firm's shares rose almost 2% in recent trading on Friday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。